Han Kwang-Eon, Kim Jinho, Kim Su-Jin, Shin Jonghoon, Choi Eun-Jung, Kim Sangmin, Lee Dogyu, Kim Jeongyun, Moon Sangwoo, Lee Ji-Eun
Department of Ophthalmology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan 43241, Republic of Korea.
Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan 43241, Republic of Korea.
J Clin Med. 2024 Oct 23;13(21):6341. doi: 10.3390/jcm13216341.
: This study assessed the efficacy of intense pulsed light (IPL) therapy for treating meibomian gland dysfunction (MGD), a key contributor to evaporative dry eye disease (DED), by comparing outcomes in patients with idiopathic MGD versus those with MGD induced by glaucoma medications. : In a retrospective analysis of 45 patients, divided into groups based on glaucoma medication use (20 patients) and non-use (25 patients), all underwent four IPL sessions combined with meibomian gland expression (MGX) at 3-week intervals. Key metrics evaluated included Ocular Surface Disease Index (OSDI) scores, tear breakup time (TBUT), Schirmer I test scores, and meibography scores, pre- and post-treatment. : Significant improvements were observed in both groups across all parameters post-treatment, indicating enhanced tear film stability and meibomian gland function. The non-glaucoma group showed slightly greater improvements, suggesting the potential impact of glaucoma medications on MGD management. : These findings underscore IPL therapy's effectiveness in improving DED symptoms and meibomian gland function, highlighting its utility as a treatment option for patients with MGD, including those on glaucoma medications.
本研究通过比较特发性睑板腺功能障碍(MGD)患者与青光眼药物诱发的MGD患者的治疗结果,评估了强脉冲光(IPL)治疗睑板腺功能障碍(MGD,蒸发型干眼疾病(DED)的关键因素)的疗效。在一项对45例患者的回顾性分析中,根据是否使用青光眼药物将患者分为两组(使用青光眼药物组20例,未使用青光眼药物组25例),所有患者均接受4次IPL治疗,并每隔3周进行一次睑板腺按摩(MGX)。评估的关键指标包括治疗前后的眼表疾病指数(OSDI)评分、泪膜破裂时间(TBUT)、Schirmer I试验评分和睑板腺造影评分。治疗后两组所有参数均有显著改善,表明泪膜稳定性和睑板腺功能增强。未患青光眼组的改善略大,提示青光眼药物对MGD治疗可能有影响。这些发现强调了IPL治疗在改善DED症状和睑板腺功能方面的有效性,突出了其作为MGD患者(包括使用青光眼药物的患者)治疗选择的实用性。